LKQ Cuts FY2026 EPS Guidance Further as Strategic Review and Activist Pressure Intensify

What happened

LKQ shares have fallen about 25% year-to-date as of October 2026, extending a decline driven by lower repairable claims and tariff-related margin pressure. The company lowered fiscal 2026 adjusted EPS guidance to $2.60–$2.90, below the prior range of $2.90–$3.20, confirming that North America volumes and mix remain weak. The board's strategic alternatives review continues, and activist investors have now become involved, raising the odds of a Specialty divestiture or whole-company sale. While the stock trades at an undemanding 8.3x forward EPS and yields 5.4%, the absence of a definitive transaction timeline and ongoing operational deterioration keep uncertainty high. The market appears to be discounting the low valuation due to execution risk on both the operating turnaround and the strategic process.

Implication

The reduced EPS range pushes the risk-reward closer to the bear case, as the prior base case assumed earnings stability near $3.00 and now appears too optimistic. Activist involvement could accelerate value-unlocking actions, but it may also lead to a fire sale if the business continues to weaken. The stock's low multiple and dividend yield provide some downside cushion only if free cash flow remains near the guided range and the Specialty sale achieves a reasonable price. Investors should monitor upcoming quarterly results for signs that repairable claims are bottoming and that North America margins are stabilizing, as these are prerequisites for a re-rating. A more constructive stance would be warranted only after a definitive strategic agreement is announced or after two consecutive quarters of organic volume improvement in North America.

Thesis delta

The master report's WAIT rating is now under pressure because LKQ cut FY2026 EPS guidance below the $2.90 threshold that was a stated trigger for downgrade. The emergence of activist involvement adds a potential catalyst but does not offset the operational deterioration. The thesis shifts from 'wait for stabilization' to 'require strategic evidence before any position.'